Evolving treatment options for melanoma brain metastases (Q38598521)

4 September 2017

title

Evolving treatment options for melanoma brain metastases (English)

1 reference

4 September 2017

3

Kate Fife

1 reference

4 September 2017

Thankamma Ajithkumar

1

1 reference

4 September 2017

Christine Parkinson

series ordinal

2

1 reference

4 September 2017

Pippa Corrie

series ordinal

4

1 reference

4 September 2017

Sarah Jefferies

series ordinal

5

1 reference

4 September 2017

publication date

1 October 2015

1 reference

Lancet Oncology Commission

4 September 2017

published in

1 reference

4 September 2017

volume

16

1 reference

4 September 2017

issue

13

1 reference

4 September 2017

page(s)

e486-97

1 reference

Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma.

4 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900141-2

7 January 2021

Determinants of outcome in melanoma patients with cerebral metastases

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900141-2

7 January 2021

Melanoma brain metastasis: overview of current management and emerging targeted therapies.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900141-2

7 January 2021

Management of melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900141-2

7 January 2021

Predictive factors for the development of brain metastases in patients with malignant melanoma: a study by the Anatolian society of medical oncology

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900141-2

7 January 2021

Malignant melanoma and central nervous system metastases: incidence, diagnosis, treatment and survival

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900141-2

7 January 2021

Predictive factors for the development of brain metastasis in advanced unresectable metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900141-2

7 January 2021

NRAS mutation status is an independent prognostic factor in metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900141-2

7 January 2021

Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900141-2

7 January 2021

Treatment of melanoma metastases in the brain

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900141-2

7 January 2021

A variety of appearances of malignant melanoma in the head: a review

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900141-2

7 January 2021

Morphological and functional MRI, MRS, perfusion and diffusion changes after radiosurgery of brain metastasis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900141-2

7 January 2021

Response assessment criteria for brain metastases: proposal from the RANO group.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900141-2

7 January 2021

Melanoma cells show a heterogeneous range of sensitivity to ionizing radiation and are radiosensitized by inhibition of B-RAF with PLX-4032.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900141-2

7 January 2021

A prognostic index that predicts outcome following palliative whole brain radiotherapy for patients with metastatic malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900141-2

7 January 2021

Whole-brain radiotherapy in patients with brain metastases from melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900141-2

7 January 2021

The palliation of brain metastases: Final results of the first two studies by the radiation therapy oncology group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900141-2

7 January 2021

Whole brain radiotherapy for the treatment of newly diagnosed multiple brain metastases

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900141-2

7 January 2021

Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900141-2

7 January 2021

Preservation of memory with conformal avoidance of the hippocampal neural stem-cell compartment during whole-brain radiotherapy for brain metastases (RTOG 0933): a phase II multi-institutional trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900141-2

7 January 2021

Whole brain radiotherapy after local treatment of brain metastases in melanoma patients--a randomised phase III trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900141-2

7 January 2021

Low incidence of melanoma brain metastasis in the hippocampus

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900141-2

7 January 2021

Estimated risk of perihippocampal disease progression after hippocampal avoidance during whole-brain radiotherapy: safety profile for RTOG 0933.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900141-2

7 January 2021

Whole brain helical Tomotherapy with integrated boost for brain metastases in patients with malignant melanoma-a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900141-2

7 January 2021

Analysis of radiosurgical results in patients with brain metastases according to the number of brain lesions: is stereotactic radiosurgery effective for multiple brain metastases?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900141-2

7 January 2021

A randomized trial of surgery in the treatment of single metastases to the brain

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900141-2

7 January 2021

Treatment of single brain metastasis: radiotherapy alone or combined with neurosurgery?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900141-2

7 January 2021

The choice of treatment of single brain metastasis should be based on extracranial tumor activity and age.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900141-2

7 January 2021

A randomized trial to assess the efficacy of surgery in addition to radiotherapy in patients with a single cerebral metastasis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900141-2

7 January 2021

Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900141-2

7 January 2021

Stereotactic radiosurgery boost to the resection cavity for cerebral metastases: Report of overall survival, complications, and corticosteroid protocol

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900141-2

7 January 2021

Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900141-2

7 January 2021

Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900141-2

7 January 2021

Stereotactic radiosurgery plus whole brain radiotherapy versus radiotherapy alone for patients with multiple brain metastases

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900141-2

7 January 2021

A multiinstitutional outcome and prognostic factor analysis of radiosurgery for resectable single brain metastasis.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900141-2

7 January 2021

Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900141-2

7 January 2021

First interim analysis of a randomised trial of whole brain radiotherapy in melanoma brain metastases confirms high data quality.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900141-2

7 January 2021

Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900141-2

7 January 2021

A prospective randomized multicentre phase III trial of fotemustine plus whole brain irradiation versus fotemustine alone in cerebral metastases of malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900141-2

7 January 2021

Safety and efficacy of high-dose interleukin-2 therapy in patients with brain metastases

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900141-2

7 January 2021

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900141-2

7 January 2021

Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900141-2

7 January 2021

Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900141-2

7 January 2021

Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900141-2

7 January 2021

Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900141-2

7 January 2021

Ipilimumab in the real world: the UK expanded access programme experience in previously treated advanced melanoma patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900141-2

7 January 2021

Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900141-2

7 January 2021

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900141-2

7 January 2021

Pembrolizumab versus Ipilimumab in Advanced Melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900141-2

7 January 2021

Vemurafenib for melanoma metastases to the brain

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900141-2

7 January 2021

Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900141-2

7 January 2021

Response rate to vemurafenib in patients with B-RAF-positive melanoma brain metastases: a retrospective review

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900141-2

7 January 2021

A Retrospective Evaluation of Vemurafenib as Treatment for BRAF-Mutant Melanoma Brain Metastases.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900141-2

7 January 2021

Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900141-2

7 January 2021

Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900141-2

7 January 2021

Patterns of response and progression in patients with BRAF-mutant melanoma metastatic to the brain who were treated with dabrafenib

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900141-2

7 January 2021

Improved survival with MEK inhibition in BRAF-mutated melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900141-2

7 January 2021

Improved overall survival in melanoma with combined dabrafenib and trametinib

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900141-2

7 January 2021

Neoadjuvant treatment of a solitary melanoma brain metastasis with vemurafenib

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900141-2

7 January 2021

Factors influencing the CNS distribution of a novel MEK-1/2 inhibitor: implications for combination therapy for melanoma brain metastases

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900141-2

7 January 2021

Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900141-2

7 January 2021

Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900141-2

7 January 2021

Ipilimumab and radiation therapy for melanoma brain metastases

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900141-2

7 January 2021

Survival of melanoma patients with brain metastases treated with ipilimumab and stereotactic radiosurgery

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900141-2

7 January 2021

Ipilimumab in melanoma with limited brain metastases treated with stereotactic radiosurgery.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900141-2

7 January 2021

Ipilimumab and Stereotactic Radiosurgery Versus Stereotactic Radiosurgery Alone for Newly Diagnosed Melanoma Brain Metastases.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900141-2

7 January 2021

Immune modulation in advanced radiotherapies: Targeting out-of-field effects

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900141-2

7 January 2021

Immunologic correlates of the abscopal effect in a patient with melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900141-2

7 January 2021

Vemurafenib and radiation therapy in melanoma brain metastases

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900141-2

7 January 2021

Vemurafenib and radiosensitization.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900141-2

7 January 2021

A systematic approach to the management of patients with brain metastases of known or unknown primary site

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900141-2

7 January 2021

Microsurgery for the treatment of primary malignant intracranial melanoma: a surgical series and literature review

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900141-2

7 January 2021

Primitive cerebral melanoma: case report and review of the literature.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900141-2

7 January 2021

10.1016/S1470-2045(15)00141-2

Identifiers

DOI

1 reference

4 September 2017

1 reference